{"id":"cp-690-550-tofacitinib","safety":{"commonSideEffects":[{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Elevated cholesterol"},{"rate":null,"effect":"Increased creatinine"},{"rate":null,"effect":"Herpes zoster reactivation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tofacitinib selectively inhibits JAK1 and JAK3 (and to a lesser extent JAK2), which are intracellular kinases critical for signal transduction downstream of cytokine receptors including IL-2, IL-7, and IL-15. By blocking JAK-STAT signaling, the drug suppresses T-cell proliferation and reduces production of pro-inflammatory cytokines, thereby dampening the adaptive immune response in autoimmune and inflammatory conditions.","oneSentence":"Tofacitinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:51.113Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ulcerative colitis"},{"name":"Polyarticular course juvenile idiopathic arthritis"},{"name":"Psoriasis"},{"name":"Atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT03000439","phase":"PHASE3","title":"A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-05-10","conditions":"Arthritis Juvenile Idiopathic","enrollment":100},{"nctId":"NCT01743677","phase":"PHASE1","title":"CP-690,550 Thorough QTc Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-10-26","conditions":"Healthy","enrollment":60},{"nctId":"NCT01815424","phase":"PHASE3","title":"A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-12","conditions":"Psoriasis","enrollment":266},{"nctId":"NCT01458574","phase":"PHASE3","title":"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-07-20","conditions":"Ulcerative Colitis","enrollment":593},{"nctId":"NCT01465763","phase":"PHASE3","title":"A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-04","conditions":"Ulcerative Colitis","enrollment":614},{"nctId":"NCT01458951","phase":"PHASE3","title":"A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-06","conditions":"Ulcerative Colitis","enrollment":547},{"nctId":"NCT02001181","phase":"PHASE2","title":"Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-12","conditions":"Dermatitis, Atopic","enrollment":69},{"nctId":"NCT01519089","phase":"PHASE3","title":"A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-03","conditions":"Psoriasis","enrollment":95},{"nctId":"NCT00263328","phase":"PHASE2","title":"Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-12","conditions":"Kidney Transplantation","enrollment":46},{"nctId":"NCT00661661","phase":"PHASE3","title":"Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-04","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT01262118","phase":"PHASE1","title":"Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-05","conditions":"Rheumatoid Arthritis","enrollment":69},{"nctId":"NCT01740362","phase":"PHASE1","title":"Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-10","conditions":"Renal Impairment","enrollment":24},{"nctId":"NCT00550446","phase":"PHASE2","title":"A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-09","conditions":"Arthritis, Rheumatoid","enrollment":386},{"nctId":"NCT01731327","phase":"PHASE1","title":"A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-11","conditions":"Healthy","enrollment":20},{"nctId":"NCT01710020","phase":"PHASE1","title":"Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-02","conditions":"End-Stage Renal Disease, Hemodialysis","enrollment":12},{"nctId":"NCT01059864","phase":"PHASE2","title":"Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-02","conditions":"Rheumatoid Arthritis","enrollment":111},{"nctId":"NCT01499004","phase":"PHASE1","title":"A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-11","conditions":"Healthy","enrollment":30},{"nctId":"NCT01202240","phase":"PHASE1","title":"Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-09","conditions":"Healthy","enrollment":12},{"nctId":"NCT01204112","phase":"PHASE1","title":"Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-09","conditions":"Healthy","enrollment":12},{"nctId":"NCT01185184","phase":"PHASE1","title":"Pharmacokinetics And Safety Study Of Two CP-690,550 Controlled Release Formulation Following Single Dose In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-08","conditions":"Healthy","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Matching placebo to tofacitinib (same tablet or solution as the active arm)."],"phase":"phase_3","status":"active","brandName":"CP-690,550 (tofacitinib)","genericName":"CP-690,550 (tofacitinib)","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tofacitinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation. Used for Rheumatoid arthritis, Ulcerative colitis, Polyarticular course juvenile idiopathic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}